| CHMP2B | |
|---|---|
| Gene | [CHMP2B](/genes/chmp2b) |
| UniProt | Q9UQN3 |
| PDB | N/A |
| Mol. Weight | 24 kDa |
| Localization | [Endosomes and endolysosomal membranes](/mechanisms/lysosome-dysfunction) |
| Family | [ESCRT-III complex](/entities/autophagy) family |
| Diseases | [Frontotemporal Dementia](/diseases/ftd), ALS5 |
Chmp2B is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CHMP2B is a protein encoded by the CHMP2B gene. It belongs to the ESCRT-III complex family family and has a molecular weight of approximately 24 kDa[1]. This protein is localized to Endosomes and endolysosomal membranes and plays a significant role in the pathogenesis of Frontotemporal Dementia, ALS.
CHMP2B has been characterized structurally through X-ray crystallography and cryo-EM. Available PDB structures include: No structures deposited.
The protein's three-dimensional structure can also be explored via the AlphaFold Protein Structure Database.
Under physiological conditions, CHMP2B performs essential functions in the nervous system. It is primarily found in Endosomes and endolysosomal membranes and contributes to normal cellular homeostasis, signaling, and neuronal function.
CHMP2B is a member of the ESCRT-III (Endosomal Sorting Complex Required for Transport III) machinery, which plays critical roles in:
The ESCRT-III complex consists of multiple charged multivesicular body proteins (CHMP2A, CHMP2B, CHMP4A/B/C, CHMP6, CHMP7) that polymerize on endosomal membranes to drive vesicle budding.
Several pathogenic mutations in CHMP2B have been linked to familial frontotemporal dementia (FTD) and ALS:
These mutations lead to endolysosomal dysfunction, characterized by:
Given CHMP2B's central role in endolysosomal trafficking, therapeutic strategies include:
CHMP2B interacts with several key proteins in its function:
CHMP2B is implicated in the following neurodegenerative conditions:
Misfolding, aggregation, or dysfunction of CHMP2B contributes to neuronal damage through various mechanisms including proteotoxic stress, disrupted cellular signaling, and neuroinflammation.
CHMP2B represents an important therapeutic target. Multiple drug development programs are exploring strategies to modulate its function, reduce toxic forms, or enhance clearance mechanisms.
The study of Chmp2B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.